Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Nat Med ; 73(3): 468-479, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30739283

ABSTRACT

The Kampo medicine yokukansan (YKS) has a wide variety of properties such as anxiolytic, anti-inflammatory and analgesic effects, and is also thought to regulate tumor suppression. In this study, we investigated the anti-tumor effect of YKS. We used Lewis lung carcinoma (LLC)-bearing mice that were fed food pellets containing YKS and then performed a fecal microbiota analysis, a microarray analysis for microRNAs (miRNAs) and an in vitro anti-tumor assay. The fecal microbiota analysis revealed that treatment with YKS partly reversed changes in the microbiota composition due to LLC implantation. Furthermore, a miRNA array analysis using blood serum showed that treatment with YKS restored the levels of miR-133a-3p/133b-3p, miR-1a-3p and miR-342-3p following LLC implantation to normal levels. A TargetScan analysis revealed that the epidermal growth factor receptor 1 signaling pathway is one of the major target pathways for these miRNAs. Furthermore, treatment with YKS restored the levels of miR-200b-3p and miR-200c-3p, a recognized mediator of cancer progression and controller of emotion, in the hypothalamus of mice bearing LLC. An in vitro assay revealed that a mixture of pachymic acid, saikosaponins a and d and isoliquiritigenin, which are all contained in YKS, exerted direct and additive anti-tumor effects. The present findings constitute novel evidence that YKS may exert an anti-tumor effect by reversing changes in the fecal microbiota and miRNAs circulating in the blood serum and hypothalamus, and the compounds found in YKS could have direct and additive anti-tumor effects.


Subject(s)
Medicine, Kampo/methods , Neoplasms/drug therapy , Animals , Anti-Anxiety Agents/pharmacology , Humans , Male , Mice
2.
Int J Surg Case Rep ; 14: 172-4, 2015.
Article in English | MEDLINE | ID: mdl-26279261

ABSTRACT

INTRODUCTION: It is commonly thought that Salter-Harris type I or II appears in mallet fingers in childhood, with S-H type III appearing in adolescence. PRESENTATION OF CASE: We present a case of bony mallet finger in childhood. Radiographs showed a small fragment above the distal interphalangeal joint, and this fragment was separated from the dorsal epiphysis without injury to the epiphyseal plate. Open reduction and fixation were performed and bone union was achieved without complications. DISCUSSION: Bony mallet finger in childhood manifests as S-H types I, II, and III in typical cases. However, it depends on narrowing of the epiphysis and the strength of the axial forces on the tip of the distal phalanx. In the case of epiphysis narrowing and only small forces affecting the region, an avulsion fracture without injury to the epiphyseal plate will occur in rare cases. CONCLUSION: We presented here a rare case of a bony mallet finger in childhood without epiphyseal plate injury.

4.
Neuropsychiatr Dis Treat ; 10: 1727-42, 2014.
Article in English | MEDLINE | ID: mdl-25246794

ABSTRACT

Japanese traditional herbal medicine (Kampo) has its origins in traditional Chinese medicine (TCM). It was introduced to Japan in the middle of the sixth century and has evolved over the past 1,400 years after combining with Japan's original folk remedies. While it retains some similarities to TCM, Kampo has evolved in Japan, resulting in a system of medicine that has many differences from TCM. Kampo medicine is considered to be very safe; in Japan, Kampo herbal formulas are manufactured by licensed pharmaceutical companies, prescribed by Western-trained medical doctors (usually as a freeze-dried extract), and have quality control standards similar to those of prescription drugs. The present study examined Yokukan-san (Yi-Gan San in TCM), a Kampo formula that has been used empirically in Japan for more than 400 years. Accumulating clinical trials have demonstrated Yokukan-san's efficacy in treating patients with behavioral and psychological symptoms of dementia, which has resulted in the Japanese Society of Neurology listing it in the Japanese Guidelines for the Management of Dementia 2010. Efficacy in other diseases and conditions, such as sleep disorders, tardive dyskinesia, aggression, and impulsivity has also been reported. This article reviews both clinical and basic studies of Yokukan-san, with the goal of clarifying its clinical indications.

SELECTION OF CITATIONS
SEARCH DETAIL
...